Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 6, 2005, Pages 885-892

  Hellings, Jessica A ^a,d   Zarcone, Jennifer R ^a   Valdovinos, Maria G ^b   Reese, R Matthew ^a   Gaughan, Eric ^a   Schroeder, Stephen R ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b L and C Tower   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; RISPERIDONE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; AUTISM; AUTOMUTILATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENDER; HUMAN; HYPERPROLACTINEMIA; MAINTENANCE THERAPY; MENTAL DEFICIENCY; PROLACTIN RELEASE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; HYPERPROLACTINEMIA; LONG-TERM CARE; MENTAL RETARDATION; PROLACTIN; PROSPECTIVE STUDIES; RISPERIDONE; SEX FACTORS; TREATMENT OUTCOME;

EID: 29944441899     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.885     Document Type: Article

References (33)

1. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL: Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12:83-91, 2002.
2. Aman MG, Burrow WH, Wolford PL: The Aberrant Behavior Checklist-Community: Factor validity and effect of subject variables for adults in group homes. Am J Ment Retard 100:283-292, 1995.
3. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, (DC), American Psychiatric Association, 1994.
5. Colao A, Loche S, Cappa M, DeSarno A, Landi M, Sarnacchiaro F, Faccioli G, Lombardi G: Prolactinomas in children and adolescents: Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777-2780, 1998.
6. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
7. Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M: High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 27:467-478, 1997.
8. Gualtieri CT: The Neuroleptic Side Effects Checklist. Unpublished scale available from the author, 1984.
9. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR: Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. J Child Adoles Psychopharmacol 11:229-238, 2001.
10. Hellings JA, Zarcone JR, Reese RM, Valdovinos MG, Marquis JG, Fleming KK, Schroeder SR: A crossover study of risperidone in children, adolescents, and adults with mental retardation. J Autism Devel Disord (In press).
11. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57-61, 1999.
12. Leiter R: Leiter International Performance Scale. Chicago: Stoelting Co., 1994.
13. Masi G, Cosenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-394, 2001.
14. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998.
15. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology (Berl) 99:445-449, 1989.
16. Munarriz R, Bennett L, Goldstein I: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:1890-1891 (author reply 1890-1891), 2002.
17. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-376, 1998.
18. Pappagallo M, Silva R: The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adoles Psychopharmacol 14:359-371, 2004.
19. Posey DJ, Walsh KH, Wilson GA, McDougle CJ: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 9:273-276, 1999.
20. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
21. Saito E, Correll UC, Kafantaris V: Hyperprolactinemia in children and adolescents treated with atypical antipsychotics: Abstract. J Child Adolesc Psychopharmacol 13:412, 2003.
22. Sandler L: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:1890-1891 (author reply 1890-1891), 2002.
23. Schroeder SR, Rojahn J, Reese RM: Brief report: Reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. J Autism Dev Disord 27:89-102, 1997.
24. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
25. Sprague RL, Kalachnik JE, Slaw KM, Shaw KM: Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS). Ment Retard 27:141-148, 1989.
26. Stanniland C, Taylor D: Tolerability of atypical antipsychotics. Drug Saf 22:195-214, 2000.
27. Tandon R: Improvement without impairment: A review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol 23:S15-S20, 2003.
28. Valiquette G: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:1890-1891 (author reply 1890-1891), 2002.
29. Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P, Bark N: High-dose treatment with haloperidol: The effect of dose reduction. J Clin Psychopharmacol 20:252-256, 2000.
30. Wechsler D: Manual for the Wechsler Adult Intelligence Scale-Revised. San Antonio (TX), Psychological Corp., 1981.
31. Wechsler D: Manual for the Wechsler Intelligence Scale for Children, Third Edition, San Antonio (TX), Psychological Corp., 1991.
32. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.
33. Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, Fleming K, Shores R, Williams D, Schroeder SR: Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard 106:525-538, 2001.